Search
Metyrapone
go.drugbank.com/drugs/DB01011ApprovedInvestigationalAn inhibitor of the enzyme steroid 11-beta-monooxygenase. It is used as a test of the feedback hypothalamic-pituitary mechanism in the diagnosis of cushing syndrome.
Echothiophate
go.drugbank.com/drugs/DB01057ApprovedInvestigationalA potent, long-acting irreversible cholinesterase inhibitor used as an ocular hypertensive in the treatment of glaucoma. Occasionally used for accomodative esotropia.
Synonyms: 2-(Diethoxyphosphorylsulfanyl)ethyl-N,N,N-trimethylazanium iodideDarvadstrocel
go.drugbank.com/drugs/DB16581ApprovedInvestigationalWithdrawn[L39759] It is the first mesenchymal stem cell therapy approved in Europe for this therapeutic indication. … It is indicated for the treatment of complex perianal fistulas in adult patients with non-active or mildly active luminal Crohn’s disease when fistulas have shown an inadequate response to at least one
Siponimod
go.drugbank.com/drugs/DB12371ApprovedInvestigational[L5801] MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792] … [L12171] This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA
Clorazepic acid
go.drugbank.com/drugs/DB00628ApprovedIllicitClorazepic acid (clorazepate) is a water-soluble benzodiazepine with muscle-relaxant and anticonvulsant actions effective in the treatment of anxiety. … In September 2020, a black box warning describing these risks was included on the product label of benzodiazepines as per FDA regulation.
Mephentermine
go.drugbank.com/drugs/DB01365ApprovedWithdrawnA sympathomimetic agent with mainly indirect effects on adrenergic receptors. It is used to maintain blood pressure in hypotensive states, for example, following spinal anesthesia.
Mavacamten
go.drugbank.com/drugs/DB14921ApprovedInvestigationalIt received initial US FDA approval in 2022, and it is one of the first myosin inhibitors to be used in humans. … [A248440] Mavacamten was also approved by Health Canada in October 2022 and by EMA in July 2023 for the same indication.[L44106,L47471]
Imiquimod
go.drugbank.com/drugs/DB00724ApprovedInvestigationalImiquimod is an immune response modifier that acts as a toll-like receptor 7 agonist. Imiquimod is commonly used topically to treat warts on the skin of the genital and anal areas. … Imiquimod does not fight the viruses that cause warts directly, however, it does help to relieve and control wart production.
AP5280
go.drugbank.com/drugs/DB05112ExperimentalAP5280 is a novel N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-bound platinum (Pt) therapeutic designed to increase the therapeutic index relative to conventional, small-molecule platinum agents.
Butalbital
go.drugbank.com/drugs/DB00241ApprovedIllicitThere have not been clinical trials that evaluate the clinical efficacy of butalbital in migraines [A177754] thus it is not indicated for such condition. … Due to these risks, the use of butalbital-containing combination products is typically limited for use only in cases where other medications are deemed ineffective and such usage is advised to be carefully
Synonyms: 5-allyl-5-(2'-methyl-n-propyl) barbituric acid